CCA
ACOR

Canyon Capital Advisors’s Acorda Therapeutics ACOR Stock Holding History

Canyon Capital Advisors’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-59,699
Closed -$357K – 42
2022
Q3 		$357K Hold
59,699
– – 0.04% 21
2022
Q2 		$556K Buy
59,699
+27,247
+84% +$484K 0.04% 22
2022
Q1 		$1.04M Hold
32,452
– – 0.04% 56
2021
Q4 		$1.55M Buy
32,452
+12,807
+65% +$882K 0.05% 75
2021
Q3 		$1.81M Hold
19,645
– – 0.06% 81
2021
Q2 		$1.87M Buy
19,645
+9,826
+100% +$859K 0.07% 71
2021
Q1 		$956K Buy
+9,819
New +$1.21M 0.04% 75

Other funds holding ACOR

DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
SC
Saltoro Capital Dallas, Texas $30K AUM 24.79% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Canyon Capital Advisors's ACOR Position: Q4 2022 in Review

Canyon Capital Advisors sold out of Acorda Therapeutics (ACOR) in Q4 2022, closing a stake of 59,699 shares — an estimated $357K sold.

Canyon Capital Advisors first reported a position in ACOR in Q1 2021 and held it in 7 quarters. The position peaked at $1.87M in Q2 2021. 34 funds tracked by Wall St. Rank hold ACOR as of Q4 2022.

  • Canyon Capital Advisors reported no remaining Acorda Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Canyon Capital Advisors sold 59,699 Acorda Therapeutics shares in Q4 2022, an estimated $357K.
  • Canyon Capital Advisors first reported a position in Acorda Therapeutics in Q1 2021 and held it in 7 quarters.
  • Canyon Capital Advisors's Acorda Therapeutics position peaked at $1.87M in Q2 2021.
  • 34 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2022.

Based on Canyon Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.